A Phase 2 interventional study of R2R01 and Placebo in Acute Kidney Injury, sponsored by River 2 Renal Corp.. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by River 2 Renal Corp. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Acute Kidney Injury with a site in Italy — 16 open to participants now, 19 under way, none of them phase 3. Acute Kidney Injury · Italy.
Among the 73 studies in Acute Kidney Injury with a site in Italy, this one is the 12th largest by planned enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 14 of the 18 other live ones, and was the 71st registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.
Browse Acute Kidney Injury studies →16 of the 73 studies in Acute Kidney Injury with a site in Italy are open now. Recruiting first, the newest first:
Hospital Las Higueras · Sites in Italy, Brazil, Chile and 4 more countries
Ages 18+
Uppsala University · Sites in Italy, Australia, Brazil and 7 more countries
Ages 0–16
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 18–80
Università Vita-Salute San Raffaele · Sites in Italy, Croatia
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7 · Phase 4 8
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 430 is above the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.
Median enrollment 254 across the 36 interventional studies, 520 across the 37 observational. Of the 46 that completed or were terminated, 5 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 73 have an industry lead sponsor. The 10 most frequent:
River 2 Renal Corp. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
River 2 Renal Corp. has 2 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
6 of the studies in Acute Kidney Injury with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT06697730Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoStudy of the Incidence and Prognosis of Intrahospital Acute Kidney Injury | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
| NCT07625553River 2 Renal Corp.Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury | 2027-04-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Acute Kidney Injury with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated - Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB).
Subjects are eligible for screening if they are scheduled for non-emergent CABG, valve surgery, surgery of the ascending part of the aorta, or a combination of the above, involving CPB, within 4 weeks after screening. In addition, subjects are eligible if AKI risk factors are present (at screening): a. If isolated surgery (CABG, single valve surgery, or of the ascending part of the aorta surgery) is scheduled, at least two AKI risk factors should be present b. If combined surgery is scheduled, at least one AKI risk factor should be present Risk factors for AKI are defined below: • Chronic kidney disease (CKD) stage III • Diabetes mellitus on pharmacological treatment • Confirmed diagnosis of hypertension • Documented history of Chronic Heart Failure with New York Heart Association (NYHA) class III or higher
claudication, carotid occlusion or >50% stenosis, amputation for arterial disease, previous or planned intervention on the abdominal aorta, limb arteries or carotids.
The study consists of:
A. An Open-Label Safety Run-In Part, followed by B. A Double-Blind, Placebo-Controlled, Randomized Part A. An Open-Label Safety Run-In Part The first 10 subjects will be treated with R2R01 5.0 mg SC to ascertain its safety in this population. The Safety Run-In part will be run at the San Raffaele Hospital in Milan (PI Dr. Landoni). Data collected will include but will not be limited to:
(1) detailed hemodynamic parameters; (2) use of vasopressors and/or inotropic agents during surgery and in the postoperative period; (3) incidence, severity, and relationship of adverse events (AEs), including serious adverse events (SAEs); (4) postoperative clinical course; (5) available PK data.
A Scientific Review Committee (SRC), consisting of three CSA-AKI experts and at least one medical representative of the Sponsor, will review the data from the 5.0 mg dose cohort (open-label Part), based on the safety and available pharmacokinetic data collected from the 10 enrolled patients through postoperative Day 7 or discharge, whichever occurs first. If the SRC agrees to proceed with the 5.0 mg dose, enrollment will open to the randomized part B of the study. If instead, the SRC determines that the 5.0 mg dose is not appropriate, a new dose (i.e., 2.5 mg) will be selected by the SRC for evaluation in 10 additional subjects enrolledin the open-label safety run-in part. Upon completion of the Open-Label Safety Run-In Part, and once the SRC has determined the appropriate R2R01 dose(s) to be tested, enrollment will open to the Double-Blind, Placebo-Controlled, Randomized Part. B. Double-Blind, Placebo-Controlled, Randomized Part Approximately 430 patients will be randomly assigned in a 1:1:1 manner to receive one of the two doses of R2R01or placebo. At randomization, patients will be stratified by presence of CKD stage III (strata: eGFR 59-30 ml/min/1.73m2 vs. eGFR ≥60 ml/min/1.73m2). The randomized part will be conducted at all investigational sites.
AKI will be staged according to KDIGO as follows: Stage 1: increase in SCr ≥0.3 mg/dL or an increase in serum creatinine ≥1.5-fold to 2-fold from baseline.
Stage 2: incrincrease in SCr >2-fold to 3-fold from baseline. Stage 3: increase in SCr >3-fold or SCr ≥4.0 mg/dl or initiation of renal replacement therapy (RRT)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is scheduled for non-emergent CABG (single or multiple vessels), valve surgery (single or multiple valves), surgery of the ascending part of the aorta, or a combination of the above, involving cardiopulmonary bypass (CPB), AND risk factors for acute kidney injury (AKI) are present (at screening) as specified below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug
Drug: R2R01
Drug
Drug: R2R01
Placebo
Other: Placebo
R2R01 (i.e., 5.0 mg and 2.5 mg, or alternative doses, as recommended by the SRC)
Placebo
The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI
The outcome will be measured as: • Nature, of treatment-emergent adverse events (TEAEs).
Time frame: 18 months
The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-
The outcome will be measured as frequency of treatment-emergent adverse events (TEAEs).
Time frame: 18 months
The safety and efficacy of R2R01 for prevention of AKI (Proportion of subjects deve) after cardiac surgery (CABG, valve surgery, aortic surgery, or a combination of the above) involving CPB, in subjects with additional risk factors for developing CSA-AKI
The outcome will be measured as severity of treatment-.emergent adverse events (TEAEs).
Time frame: 18 months
Evaluation of R2R01 for the reduction of postoperative AKI severity
\- Severity grade of AKI within 7 days after start of cardiac surgery based on SCr (serum creatinine)
Time frame: 18 months
- Evaluation R2R01 for the reduction of postoperative AKI duration
Duration of AKI defined as the number of days meeting the definition of AKI
Time frame: 18 months
The efficacy of R2R01 on renal function
\- Change in SCr (serum creatinine) (and corresponding eGFR values) at postoperative hours 12, 24, 48, 72, and postoperative Days 7 and 30, versus baseline
Time frame: 18 months
- Evaluation R2R01 for the reduction of major adverse kidney events (MAKE) defined as all-cause mortality, RRT and/or ≥25% sustained reduction of kidney function compared to baseline, at postoperative Day 7, and at postoperative Day 30.
\- Proportion of subjects with a major adverse kidney event (MAKE) defined as all-cause mortality, RRT and/or ≥ 25% sustained reduction of kidney function (i.e., a reduction of eGFR of 25% or more compared to the baseline presurgery sample, using the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) equations (with either SCr, CyC, or both) at postoperative Day 7 and at postoperative Day 30
Time frame: 18 months
- Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.
\- Length of ICU stay (in hours) defined as the duration of stay in the ICU immediately following surgery (or recovery room post-surgery) until ICU discharge
Time frame: 18 months
Evaluation of the effect of R2R01 for the reduction of hospital readmissions at postoperative Day 30
Proportion of subjects readmitted to the hospital at postoperative Day 30.
Time frame: 13 months
The evaluation of the efficacy of R2R101 on renal function
Change cystatin C (and corresponding eGFR values) at postoperative hours 12, 24, 48, 72, and postoperative Days 7 and 30, versus baseline
Time frame: 18 months
- Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.
\- Lenght of Hospital stay (in days) defined as duration of stay in the hospital from the day of surgery to hospital disharge.
Time frame: 18 months
- Evaluation the effect of R2R01 on the length of postoperative stay in Intensive Care Unit (ICU) and overall hospitalization time.
\- ICU free daysn and hospital free days.
Time frame: 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.
Of 57 phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 42. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
River 2 Renal Corp.